TrialHaematologica2019

A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM).

Lionel Ades et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.